Sarepta Therapeutics (SRPT) Cash & Equivalents (2010 - 2026)

Sarepta Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $216.8 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 9.98% year-over-year to $216.8 million in Q1 2026; TTM through Mar 2026 was $216.8 million, a 9.98% decrease from a year earlier, with the FY2025 full-year figure at $801.3 million, down 5.08% from the prior year.
• Cash & Equivalents retreated to $216.8 million in Q1 2026 per SRPT's latest filing, from $801.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.2 billion in Q1 2022 and bottomed at $153.3 million in Q2 2025.
• The 5-year median for Cash & Equivalents is $541.9 million (2023), against an average of $616.0 million.
• Across the five-year window, Cash & Equivalents tumbled 63.49% in 2024 and soared 104.47% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $966.8 million in 2022, then slumped by 55.68% to $428.4 million in 2023, then surged by 97.04% to $844.2 million in 2024, then retreated by 5.08% to $801.3 million in 2025, then plunged by 72.94% to $216.8 million in 2026.
• Per Business Quant, the three latest SRPT Cash & Equivalents figures stand at $216.8 million (Q1 2026), $801.3 million (Q4 2025), and $404.6 million (Q3 2025).